November 19, 2019
11:30AM-2:00PM PST
Thermo Fisher Scientific
180 Oyster Point Blvd.
South San Francisco, CA
As the molecules being developed become increasing complex, clinical trials for biological products require experience and specialized expertise. Recently, the FDA recently issued new guidelines for developers of bispecific antibodies. For new and emerging biopharma companies, ensuring a successful IND filing in tight timelines with limited budgets is key to corporate success and survival. CDMO selection is a critical part of the journey from discovery to patient.
Meet with our subject matter experts for a technical discussion titled Novel paradigms for driving speed to clinic in monoclonal antibody development and specialized solutions for complex recombinant proteins.
At this event, you will learn:
You are invited to join us for an informative discussion on how to accelerate the path to early trials while satisfying regulatory guidelines, maintaining product quality and meeting safety requirements.